AVTX vs CB · P/E 0.0, rev $441.0K vs P/E 14, rev $59.40B
Avalo Therapeutics Inc (AVTX) versus Chubb Ltd (CB) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Not investment advice. Open the AVTX and CB stock pages for the full models.
Not investment advice.